Analyst firms · Morgan Stanley · ASND

Morgan Stanley ASND price target and rating history

Ascendis Pharma A/S (ASND) · Health Care

Morgan Stanley rates Ascendis Pharma A/S (ASND) Overweight with a $250 price target, as of its latest action on Jul 3, 2025. It has published 5 rating actions on ASND since August 2021, including 1 upgrade and 1 downgrade. Across 6 firms with a ASND price target in the last 12 months, the median target is $330.50.

Current rating
Overweight
Price target
$250
Median target, all firms
$330.50
Actions on ASND
5

Morgan Stanley price target on ASND

$250$179$10820222023202420252026
Morgan Stanley price target on ASND, each point a stated target, August 2021 to July 2025.

Every Morgan Stanley rating on ASND

How other firms rate ASND

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Raymond JamesOutperform$287Sep 15, 2026
H.C. WainwrightBuy$345Aug 27, 2026
BMO Capital MarketsOutperform$319Aug 19, 2026
CitigroupBuy$355May 19, 2026
JefferiesBuyMar 16, 2026
BarclaysOverweight$342Jan 28, 2026
Wolfe ResearchPeer Perform$255Nov 18, 2025

Questions about Morgan Stanley and ASND

What is Morgan Stanley's price target for ASND?
Morgan Stanley's latest stated price target for Ascendis Pharma A/S (ASND) is $250, from its action on Jul 3, 2025.
What is Morgan Stanley's rating on ASND?
Morgan Stanley rates ASND Overweight, a bullish rating, as of Jul 3, 2025.
When did Morgan Stanley last change its view on ASND?
On Jul 3, 2025, Morgan Stanley resumes coverage at Overweight, price target $250.
How does Morgan Stanley's ASND target compare with other analysts?
Across 6 firms with a ASND price target in the last 12 months, the median target is $330.50.

More ASND rating histories

All Morgan Stanley ratingsASND news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.